CELU CELULARITY INC

Celularity to Present at Jefferies Cell and Genetic Medicine Summit

Celularity to Present at Jefferies Cell and Genetic Medicine Summit

FLORHAM PARK, N.J., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a clinical-stage biotechnology company developing placental-derived allogeneic cell therapies, today announced that Robert Hariri, M.D., Ph.D., Founder, Chairman and Chief Executive Officer of Celularity, will present at the Jefferies Cell and Genetic Medicine Summit on Friday, September 30, 2022 at 11 a.m. ET.

A live webcast of the presentation can be accessed on the Investors section of Celularity’s website at . A replay of the webcast will be archived and available following the event for approximately 30 days.

About Celularity

Celularity Inc. (Nasdaq: CELU) headquartered in Florham Park, N.J., is a clinical stage biotechnology company leading the next evolution in cellular medicine by developing allogeneic cryopreserved off-the-shelf placental-derived cell therapies, including therapeutic programs using unmodified natural killer (NK) cells, genetically modified NK cells, T-cells engineered with a CAR (CAR T-cells), and mesenchymal-like adherent stromal cells (ASCs). These therapeutic programs target indications in cancer, infectious and degenerative diseases. In addition, Celularity develops and manufactures innovative biomaterials also derived from the postpartum placenta. Celularity believes that by harnessing the placenta’s unique biology and ready availability, it can develop therapeutic solutions that address significant unmet global needs for effective, accessible, and affordable therapies.

To learn more, visit celularity.com.

Celularity Investor Contacts:

Carlos Ramirez SVP, Investor Relations

Celularity Inc.

 



EN
27/09/2022

Underlying

CELUCELULARITY INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on CELULARITY INC

 PRESS RELEASE
Free
CELU CELULARITY INC

Celularity Reaches Binding Term Sheets on Financing Transactions to Su...

Celularity Reaches Binding Term Sheets on Financing Transactions to Support Its Strategic Vision The contemplated financing transactions would provide up to $12 Million in capital to support Celularity’s strategic priorities around longevity and preservation of human performance. FLORHAM PARK, N.J., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative and cellular medicine company addressing age-related and degenerative diseases, today announced that it has entered into two binding term sheets for a senior secured term loan and a secured convert...

December 18, 2025 1 EN
 PRESS RELEASE
Free
CELU CELULARITY INC

Celularity and DefEYE, Inc. Partner to Advance Growth of Regenerative ...

Celularity and DefEYE, Inc. Partner to Advance Growth of Regenerative Therapies in Eye Care FLORHAM PARK, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative and cellular medicine company addressing age-related and degenerative diseases, announced today a strategic partnership with DefEYE, Inc. (“DefEYE”), a newly established ophthalmic product and technology company. Celularity has executed an exclusive license & pricing arrangement with DefEYE on the backend of Celularity’s in-kind investment in DefEYE’s $12MM Series Seed Preferred Equit...

October 30, 2025 1 EN
 PRESS RELEASE
Free
CELU CELULARITY INC

Celularity Announces Peer-Reviewed Publication of Phase 2 Clinical Tri...

Celularity Announces Peer-Reviewed Publication of Phase 2 Clinical Trial Results Demonstrating the Safety and Efficacy of Human Placenta-Derived Cells (PDA-002) for Diabetic Foot Ulcers Complicated by Peripheral Artery Disease First-in-class regenerative therapy for diabetic foot ulcers complicated by peripheral artery diseaseCelularity PDA-002 achieved durable wound healing with just two intramuscular dosesAs a qualified stem cell therapy under Florida statute (§ 458.3245), effective July 1, 2025 authorizing use in wound care, orthopedics, and pain management, PDA-002 may offer licensed Fl...

October 14, 2025 1 EN
 PRESS RELEASE
Free
CELU CELULARITY INC

Celularity Announces Filing of Form 10-Q Quarterly Reports for the Fir...

Celularity Announces Filing of Form 10-Q Quarterly Reports for the First Quarter and the Second Quarter 2025, Confirmation of Nasdaq Listing Rule 5250(c)(1) Compliance Company on Friday, August 29, 2025, filed quarterly reports on Form 10-Q for the periods ended March 31, 2025, and June 30, 2025, respectively, in accord with its August 11, 2025 updated Nasdaq compliance plan.Company also announces notification by Nasdaq dated September 2, 2025, that it now complies with Nasdaq Listing Rule 5250(c)(1). FLORHAM PARK, N.J., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (...

September 3, 2025 1 EN
 PRESS RELEASE
Free
CELU CELULARITY INC

Celularity Receives Nasdaq Notice Regarding Form 10-Q

Celularity Receives Nasdaq Notice Regarding Form 10-Q FLORHAM PARK, N.J., Aug. 22, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a regenerative and cellular medicine company focused on addressing age-related and degenerative diseases, today announced that on August 21, 2025, Nasdaq notified the Company that it did not timely file its Quarterly Report on Form 10-Q for the period ended June 30, 2025. Based on this latest notice, the Company is not in compliance with Listing Rule 5250 (c)(1), which requires the Company to timely file all required pe...

August 22, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch